Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03778957
Title A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)
Acronym EMERALD-1
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN | BRA | AUS


No variant requirements are available.